13 Multivariate analysis adjusted for sex, stage, type of surgery, and adjuvant chemotherapy showed a trend toward a higher 2-year survival rate in the 56 patients (33%) who received a TKI perioperatively (96% vs 90%), but no firm conclusion can be drawn in the absence of randomization. 13 An open, randomized, Phase II trial conducted in Asia, after surgery and adjuvant chemotherapy (four cycles of pemetrexed–carboplatin), compared a 6-month course of gefinib with simple monitoring in EGFR-mutated, stage IIIA-N2 NSCLC patients.
1
—
—